scholarly journals IMMUNOGENIC RESPONSE WITH EFFICACY OF CERTAIN GUMBORO VACCINES IN BROILER

2012 ◽  
Vol 3 (1) ◽  
pp. 07-12
Author(s):  
MT Islam ◽  
MA Samad ◽  
MI Hossain
Keyword(s):  
Antibody Titre ◽  
Broiler Chickens ◽  
Booster Dose ◽  
Animal Health ◽  
Research Work ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Unvaccinated Control ◽  
Immunogenic Response

The research work was carried out to determine the immunogenic response with efficacy of six commercial Gumboro, vaccines (Nobilis® Gumboro D78 and Nobilis® Gumboro 228E, Intervet, The Netherlands; Bur-706®, Merial, France; TAD Gumboro vac® and TAD Gumboro vac forte®, Lohmann Animal Health, Germany; BursaplexTM, Merial Select, Inc. Gainesville, USA) under experimental condition in broiler chickens during the period from November 2002 to May 2003. The chickens of two groups were vaccinated with Nobilis® Gumboro D78 and Nobilis® Gumboro 228E at 14 days of age with a booster dose at 21 days of age and were challenged at 40 days of age with vvIBDV. TAD Gumboro vac® and TAD Gumboro vac forte® were inoculated into the two groups of chickens at 14 and 28 days of age and the chickens were challenged at 35 days of age with vvIBDV. Bur-706® vaccine was given to the chickens of another group at one-day-old and 14 days of age and the chickens were challenged at 28 days of age. One group of chickens was vaccinated with Bursaplex™ vaccine at 1-day-old with no booster dose and was challenged at 21 days of age. The percentage of protection in birds receiving Nobilis® Gumboro D78 and Nobilis® Gumboro 228E vaccines by intraocular route was 92.30 and 96.29 respectively, whereas the percentages of protection in birds receiving TAD Gumboro vac®, TAD Gumboro, vac forte® and Bur-706® vaccines were 95.65, 100 and 95.83 respectively. BursaplxTM provided 100% protection against challenge with vvIBDV. Chickens vaccinated with Nobilis® Gumboro D78, Nobilis® Gumboro 228E, TAD Gumboro vac®, and Bur-706®, showed significant (p < 0.05, p < 0.01) decrease in ELISA antibody titre up to the day of challenge infection. BursaplexTM vaccinated group also showed significant decrease in ELISA antibody titre by 7 days (p < 0.05) and by 14 and 21 days (p < 0.01) after primary vaccination. In case of TAD Gumboro vac forte®, 7 days (839 ± 219.34) and 14 days (258 ± 44.80) after primary vaccination, the ELISA antibody titre significantly (p < 0.01) decreased but 7 days after booster vaccination, the ELISA antibody titre significantly (p < 0.01) increased (1299 ± 37.51). All the control sera revealed significant (p < 0.01) decrease of ELISA antibody titre up to day of challenge infection. There was an insignificant increase in ELISA antibody titre 7 days after booster vaccination in case of unvaccinated control groups for TAD Gumboro vac® and TAD Gumboro vac forte® only. Nobilis® Gumboro D78, TAD Gumboro vac® and Bur-706® vaccinated groups revealed significant (p < 0.01) increase of ELISA antibody titre 7 days post-challenge while Nobilis® Gumboro 228E and BursaplexTM vaccinated groups showed significant (p < 0.05) increase of antibody titre after 7 days of challenge. Insignificant increase of antibody titre was recorded in TAD Gumboro vac forte® vaccinated group. It may be concluded that TAD Gumboro vac forte® (intermediate plus) and BursaplexTM (Merial Select, Inc. Gainesville, USA) can be used to immunize the broiler birds sufficiently against IBD. However, it is necessary to estimate the optimum vaccination timing, i.e., to determine when maternal antibodies in chicks will decline to levels that the vaccines can overcome.

scholarly journals Comparative immunogenicity of fowl cholera vaccine in Jinding ducks

2014 ◽  
Vol 30 (2) ◽  
pp. 41-45 ◽  
Author(s):  
S Sultana ◽  
S Saha ◽  
MM Amin
Keyword(s):  
Pasteurella Multocida ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Fowl Cholera ◽  
Significant Difference ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Group A ◽  
Group B

This study compared the immunogenicity of alum-precipitated formalin-killed fowl cholera vaccines (BAU-FCV and LRI-FCV) in Jinding ducks. The ducks were divided into three groups (A = 14, B = 14, C = 12). Group A was inoculated with BAU- FCV 0.5 mL and group B with LRI- FCV 1.0 mL intramuscularly (im) at the age of six weeks and group C served as unvaccinated control. Booster vaccination was administered similarly at 11 weeks of age in groups A and B. Challenge infection was given to all birds two weeks after booster vaccination. Passive Haemagglutination Assay (PHA) antibody titres in group A were 59.4 ± 4.6 21 days after primary vaccination, 137.1 ± 21.8 15 days after booster vaccination, 100.6 ± 12.9 21 days after booster vaccination, and 256.0 ± 48.4 15 days after challenge. In group B, titres were 50.3 ± 6.5, 118.9 ± 9.1, 91.4 ± 12.9, 237.7 ± 51.7, respectively, whereas titres in group C remained at ?4.0 ± 0.0. The antibody titres were insignificant when compared between pre-vaccination and 21 days after primary vaccination in both vaccinated groups (A and B). PHA antibody titres of groups A were significantly (P < 0.0001) increased at 15 days after booster and in case of group B the antibody titres were insignificant. At 15 days after challenge the antibody titres were highly significant in both groups (A and B). There was no significant difference between the two vaccinated groups. Following challenge infection with virulent Pasteurella multocida 88.9% of birds vaccinated with BAU-FCV, and 77.8% of birds vaccinated with LRI-FCV survived, while all unvaccinated birds died. Both vaccines were safe and effective. DOI: http://dx.doi.org/10.3329/bvet.v30i2.18253 Bangl. vet. 2013. Vol. 30, No. 2, 41-45

scholarly journals Effect of dose and time of vaccination on immune response of duck plague vaccine in ducks

1970 ◽  
Vol 2 (2) ◽  
pp. 117-119 ◽  
Author(s):  
MT Hossain ◽  
MA Islam ◽  
S Akter ◽  
M Sadekuzzaman ◽  
MA Islam ◽  
...  
Keyword(s):  
Immune Response ◽  
Field Isolate ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Control Group ◽  
Duck Plague Virus ◽  
Unvaccinated Control ◽  
Plague Vaccine ◽  
Group D

Effect of dose and time of vaccination on immune response of duck plague vaccine in 90 (45 of 18-day-old and 45 of 35-day-old) Jinding ducklings was studied during the period from October 2002 to March 2003. Each of both age group (18-day-old and 35-day-old) was divided into three groups as A, B, C and D, E, F respectively, consisting of 15 ducklings in each. Each duckling of groups A and B was primarily vaccinated with 0.25 ml and 0.5 ml of duck plague vaccine (LRI, Mohakhali) intramuscularly at 18 days old respectively and could not be boosted due to the death of all the ducklings of both groups within 20 days of primary vaccination. Each duckling of group D and E received 0.5 ml and 1.0 ml of duck plague vaccine (LRI, Mohakhali) intramuscularly at 35 days old respectively and ducks of both the groups boosted with 1.0 ml of vaccine 5 months after primary vaccination. Groups C and F served as unvaccinated control. 14 days after booster vaccination ducks of group D, E and F were challenged with the virulent field isolate of duck plague virus @ 1.0 ml / duck IM (104 EID50 / dose). The ducklings of group D that were vaccinated primarily at 35 days old with 0.5 ml and boosted after 5 months with 1.0 ml of duck plague vaccine had significantly (p< 0.01) higher PHA titres after 2 weeks of primary vaccination (38.4 ± 6.4), booster vaccination (153.6 ± 25.6) and challenge infection (281.6 ± 62.71) in comparison to control group (≤4, ≤4 and 20.0 ± 2.3 respectively) and all the ducks survived (100%) after challenge. The ducklings of group E that were vaccinated primarily at 35 days old and boosted after 5 months of primary vaccination with 1.0 ml of duck plague vaccine had also significantly (p< 0.01) higher PHA titres after two weeks of booster vaccination (76.8 ± 12.8) and challenge infection (153.6 ± 25.6) in comparison to control group, but only 8 (53.3%) ducks could protect the challenge infection with virulent duck plague virus. It may be concluded that ducklings below 30 days of age should not be vaccinated with duck plague vaccine. It also may be proposed that primary vaccination at 35 days old with duck plague vaccine (LRI, Mohakhali) @ 0.5 ml / duckling and booster vaccination after 5 months of primary vaccination @ 1.0 ml could be practiced for better immune response against duck plague.Key words: effect; dose; age; immune response; duck plague vaccine; ducksdoi: 10.3329/bjvm.v2i2.2542Bangl. J. Vet. Med. (2004). 2 (2): 117-119

scholarly journals Field Investigation on the Efficacy of Salmonella Vaccine Prepared at Bangladesh Agricultural University

2015 ◽  
Vol 13 (1) ◽  
pp. 5-9
Author(s):  
MAS Bag ◽  
MM Amin ◽  
MB Rahman ◽  
YA Arafat ◽  
M Salim ◽  
...  
Keyword(s):  
Research Work ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Field Investigation ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
On Farm

The research work was performed to investigate the immunogenicity of Salmonella vaccine produced at LPVRPC, BAU Mymensingh. The vaccination was performed at the Phenix Hatchery Ltd. Gazipur in Hy-sex brown and HY-sex white chicken designated as group A and group B respectively. Group A and B were subdivided into A1, A2, A3, B1, B2 and B3 groups containing eight birds each. Group C was maintained as unvaccinated control. Birds were immunized following schedule of the LPVRPC. Each bird was vaccinated SC at six weeks of age followed by a subsequent booster dose after 45 days. After four weeks of primary vaccination the mean PHA antibody titres were 96.00±34.21 in group A1 and 96.00±34.21 in B1 group. Prebooster vaccination the mean PHA antibody titres were 88.00±33.12 in group A2 and 88.00±33.12 in B2 group. At four weeks of booster vaccination the mean PHA antibody titres were 104.00±33.12 in group A3 and 104.00±33.12 in B3 group. The mean ± PHA antibody titre in chickens of group C was ? 4.0±0.00. Salmonella vaccine prepared at (LPVRPC) Department of Microbiology and Hygiene, BAU induces satisfactory level of antibody in chickens determined by PHA test conducted in an on-farm study of layer chickens.DOI: http://dx.doi.org/10.3329/bjvm.v13i1.23705Bangl. J. Vet. Med. (2015). 13 (1): 5-9

scholarly journals EVALUATION OF MATERNALLY DERIVED ANTIBODIES AGAINST NEWCASTLE DISEASE VIRUS AND ITS EFFECT ON VACCINATION IN BROILER CHICKS

2010 ◽  
Vol 7 (2) ◽  
pp. 296-302 ◽  
Author(s):  
MA Jalil ◽  
MA Samad ◽  
MT Islam
Keyword(s):  
Immune Response ◽  
Newcastle Disease ◽  
Humoral Immune Response ◽  
Broiler Chickens ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Broiler Chicks ◽  
Humoral Immune ◽  
Different Ages ◽  
Group B

The study was conducted to determine the persistence of maternally derived antibody (MDA) and its effects on protection against NDV in broiler chickens and to investigate the status of humoral immune response following vaccination with BCRDV® (F-strain, lentogenic) at different ages of broiler chickens during the period from August to October,  2008. A total of 90 day-old broiler chicks of Cobb 500 strain with the history of vaccination of parent stock against Newcastle disease (ND) was divided into three groups (A, B and C). Birds of group A (n = 35) were used for the study of protection ability of MDA against NDV, the birds of group B (n = 45) were used for the measurement of humoral immune response in chickens following vaccination at different ages and birds of group C (n = 10) were used for the determination of persistence of maternally derived antibody. The level of antibody titre against NDV was determined by HI test. The protective potentiality of MDA and vaccine was determined by the rate of survivability of the chickens following challenge infection. It was observed that the MDA titre in day-old chicks was higher and gradually declined at minimal level at day 28. The MDA titre of 128 or above protected the birds following challenge infection with virulent NDV. There were significant decrease in HI titres of chickens which were vaccinated once at day 1 and day 7, and could not withstand challenge infection with virulent NDV. Single vaccination with BCRDV® at day 14 triggered the production of antibody but could not provide complete protection to the birds. The birds which were boosted with the same vaccine 7 days and 21 days after primary vaccination produced better immune response. However, the birds which were vaccinated primarily at day 1 and boosted at day 7 could not withstand the challenge completely. Of the other regimens of twice vaccination, primary vaccination at day 7 and booster dosing at day 28 was found to be the best in terms of immune response and protection potentiality. Therefore, it may be concluded that (a) The MDA titre level of 128 or above is sufficient to protect broilers against challenge with virulent NDV,( b) Primary vaccination at day 7 followed by a booster dosing at day 28 may be followed for better immune response and protection against ND in broilers.DOI: 10.3329/bjvm.v7i2.5995Bangl. J. Vet. Med. (2009). 7(2) : 296 – 302

scholarly journals Comparative efficacy of BAU-fowl cholera and DLS-fowl cholera vaccines in indigenous chicken

2018 ◽  
Vol 5 (2) ◽  
pp. 193-199
Author(s):  
Chamak Nahar Shampa ◽  
Suma Akter ◽  
Sukumar Saha ◽  
Md Hadiuzzaman ◽  
Azhar Ul Alam ◽  
...  
Keyword(s):  
Pasteurella Multocida ◽  
Research Work ◽  
Booster Vaccination ◽  
Indigenous Chicken ◽  
Passive Hemagglutination ◽  
Fowl Cholera ◽  
Unvaccinated Control ◽  
Group A ◽  
The Mean ◽  
Group B

The present study was conducted to determine the immune response induced in indigenous chicken produced against BAU-FC and DLS-FC vaccines with their efficacy study against Pasteurella multocida. A total of forty (40) chickens were selected and divided into Group A (15), Group B (15) and Group C (10). Group A and B were vaccinated with BAU-FCV and DLS-FCV, respectively at the dose rate of 0.5 ml through SC at six weeks of age followed by boostering at 10 weeks of age while Group C was kept as unvaccinated control. Sera samples were collected after primary and booster vaccination and antibody titre was determined by Passive hemagglutination (PHA) test. The mean PHA titres recorded at 4 weeks after primary vaccination was 51.20 ± 7.84 in birds of group A and 38.40 ± 6.40 in birds of Group B. After booster vaccination, mean PHA titer was found 140.80 ± 31.35 at 16 weeks of age in case of BAU-FC vaccinated group and 115.20 ± 12.80 in case of DLS-FC vaccinated group. The mean PHA titer was 204.80 ± 31.35 and 179.20 ± 31.35 at 19 weeks of age in birds of BAU-FC and DLS-FC vaccinated group, respectively. Birds of all groups were challenged with virulent P. multocida at 17 weeks of age. It was observed that vaccinated chickens showed maximal resistance (100%) following challenge with virulent whereas unvaccinated control birds failed to resist the challenge infection. It can be assumed from the findings of present research work that both BAU-FCV and DLS-FCV are able to protect indigenous chicken from the outbreak of avian pasteurellosis and BAU-FV vaccine showed relatively higher immuno-protective titre than that of DLS-FC vaccine.Res. Agric., Livest. Fish.5(2): 193-199, August 2018

scholarly journals Efficacy study of bio-typhoid® vaccine against fowl typhoid in backyard layer chicken

1970 ◽  
Vol 7 (2) ◽  
pp. 295-299
Author(s):  
MZ Uddin ◽  
MSR Khan ◽  
F Begum ◽  
MA Mannan
Keyword(s):  
Antibody Titre ◽  
Virulent Strain ◽  
Primary Vaccination ◽  
Control Group ◽  
Fowl Typhoid ◽  
Layer Chicken ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Group A ◽  
Group B

The study was performed with a view to isolate and identify a virulent strain of S. gallinarum and determine the purity, safety and efficacy of BIO-TYPHOID® vaccine. A total of 40 backyard layer chicken were used for this study where Group A was used for experimental vaccination, Group B kept as control and Group C was used for calculating virulent S. gallinarum challenge dose. Primary and secondary vaccination was carried out at 40 days and 110 days of age, respectively. Blood samples were collected to obtain the sera after vaccination from both vaccinated and unvaccinated control group and antibody titres were determined by Microplate agglutination test. The antibody titre increased in primary vaccination up to days 56 days post vaccination (DPV) and then decreased gradually. The highest antibody titre (Mean ± SE) 384.00 ± 42.67 was obtained at 91 DPV (21 days later of secondary vaccination) and maintained up to 98 DPV. Safety test was done by inoculating mice and purity test of the vaccine was done by inoculating on to Blood Agar media. The efficacy of BIO-TYPHOID® vaccine was recorded as 90% which was determined by challenge infection with 0.1 ml of 5x105 CFU virulent S. gallinarum. Results of this study revealed successful protections by BIO-TYPHOID® vaccine. Keywords: BIO-TYPHOID® vaccine; Chicken; Efficacy; Fowl Typhoid DOI: 10.3329/jbau.v7i2.4737 J. Bangladesh Agril. Univ. 7(2): 295-299, 2009

scholarly journals Cell-mediated and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients

2022 ◽  
Author(s):  
Lu M Yang ◽  
Cristina Costales ◽  
Muthukumar Ramanathan ◽  
Philip L. Bulterys ◽  
Kanagavel Murugesan ◽  
...  
Keyword(s):  
B Cell ◽  
Cellular Response ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Humoral Response ◽  
Primary Vaccination ◽  
Vaccine Response ◽  
Immunosuppressed Patients ◽  
S1p Receptor ◽  
Receptor Modulators

Importance: Data on the humoral and cellular immune response to primary and booster SARS-CoV-2 vaccination in immunosuppressed patients is limited. Objective: To determine humoral and cellular response to primary and booster vaccination in immunosuppressed patients and identify variables associated with poor response. Design: Retrospective observational cohort study. Setting: Large healthcare system in Northern California. Participants: This study included patients fully vaccinated against SARS-CoV-2 (mRNA-1273, BNT162b2, or Ad26.COV2.S) who underwent clinical testing for anti-SARS-SoV-2 S1 IgG ELISA (anti-S1 IgG) and SARS-CoV-2 interferon gamma release assay (IGRA) from January 1, 2021 through November 15, 2021. A cohort of 18 immunocompetent volunteer healthcare workers were included as reference. No participants had a prior diagnosis of SARS-CoV-2 infection. Exposure(s): Immunosuppressive diseases and therapies. Main Outcome(s) and Measure(s): Humoral and cellular SARS-CoV-2 vaccine response as measured by anti-S1 IgG and SARS-CoV-2 IGRA, respectively, after primary and booster vaccination. Results: 496 patients (54% female; median age 50 years) were included in this study. Among immunosuppressed patients after primary vaccination, 62% (261/419) had positive anti-S1 IgG and 71% (277/389) had positive IGRA. After booster, 69% (81/118) had positive anti-S1 IgG and 73% (91/124) had positive IGRA. Immunosuppressive factors associated with low rates of humoral response after primary vaccination included anti-CD20 monoclonal antibodies (n=48, P<.001), sphingosine 1-phsophate (S1P) receptor modulators (n=11, P<.001), mycophenolate (n=78, P=.002), and B cell lymphoma (n=55, P=.004); those associated with low rates of cellular response included S1P receptor modulators (n=11, P<.001) and mycophenolate (n=69, P<.001). Of patients who responded poorly to primary vaccination, 16% (4/25) with hematologic malignancy or primary immunodeficiency developed a significantly increased humoral response after the booster dose, while 52% (14/27) with solid malignancy, solid organ transplantation, or autoimmune disease developed an increased response (P=.009). Only 5% (2/42) of immunosuppressed patients developed a significantly increased cellular response following the booster dose. Conclusions and Relevance: Cellular vaccine response rates were higher than humoral response rates in immunosuppressed individuals after primary vaccination, particularly among those undergoing B cell targeting therapies. However, humoral response can be increased with booster vaccination, even in patients on B cell targeting therapies.

scholarly journals Determination of immune response of imported Newcastle disease virus vaccines in broiler chickens

1970 ◽  
Vol 6 (2) ◽  
pp. 139-144
Author(s):  
MS Islam ◽  
AKM Khasruzzaman ◽  
MT Hossain ◽  
MT Islam ◽  
MH Chowdhury ◽  
...  
Keyword(s):  
Immune Response ◽  
Newcastle Disease ◽  
Broiler Chickens ◽  
Geometric Mean ◽  
Primary Vaccination ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Newcastle Disease Vaccine ◽  
Group 1

A study was undertaken to determine the immune response of eight different imported live NDV vaccines in broiler chickens in the Department of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh during the period from July to December 2008. A total of 55 broiler chickens (Ross breed) were divided into eleven groups such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 of which group 1, 3, 5, 7 and 9 were vaccinated primarily with Nobilis® MA5+Clone30, Avipro® ND-IB HB1, Cevac® BIL, Newcastle-Bronchitis Vaccine Fortdodge® and Avipro® ND LaSota vaccine respectively at day 5 of age and secondarily with Nobilis® ND Clone 30, Avipro® ND LaSota, Cevac® New L, Newcastle Disease vaccine Fortdodge® and Avipro® ND LaSota vaccine respectively at day 21 of age by single eye instillation and 2, 4, 6, 8 and 10 were vaccinated with the same vaccines respectively by double eye instillation following the same schedule. Group 11 was kept as unvaccinated control. Sera samples were collected after 10 days of each vaccination and at day 5, 15, 20, 31 of age from nonvaccinated control and subjected to HI test for the determination of antibody titres. It was observed that after primary vaccination the geometric mean (GM) of HI titres of double eye vaccinated groups differed significantly (P

scholarly journals 4. MenACWY-TT Long-Term Antibody Persistence Following Adolescent Vaccination and Evaluation of a Booster Dose: A Review of Clinical Data

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S24-S24
Author(s):  
Paula Peyrani ◽  
Chris Webber ◽  
Cindy Burman ◽  
Paul Balmer ◽  
John L Perez
Keyword(s):  
Immune Responses ◽  
Conjugate Vaccine ◽  
Booster Dose ◽  
Geometric Mean ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
The United States ◽  
The European Union ◽  
Adolescent Vaccination

Abstract Background A peak in meningococcal carriage and invasive meningococcal disease (IMD) occurs during adolescence and young adulthood. In the United States, preventive vaccination with a quadrivalent meningococcal (MenACWY) conjugate vaccine is recommended at age 11–12 years, with a booster dose given at age 16 years. MenACWY-TT (Nimenrix®), a MenACWY tetanus toxoid conjugate vaccine, was first licensed in 2012 and is available in the European Union and 50 other countries. Immune responses to other MenACWY conjugate vaccines decline over several years following vaccination. Here, we review 2 recent studies evaluating the long-term persistence of MenACWY-TT immune responses in adolescents as well as safety and immunogenicity of a booster dose given 10 years after primary vaccination. Methods Both studies (ClinicalTrials.gov NCT01934140, NCT03189745) were extensions of phase 2 or 3 studies of subjects 11–17 years of age given a single dose of MenACWY-TT or MenACWY polysaccharide vaccine (MenACWY-PS). Immune responses through 10 years after primary vaccination and after a Year 10 MenACWY-TT booster dose were measured by serum bactericidal antibody assays using baby rabbit complement (rSBA). Specific endpoints included percentages of subjects with rSBA titers ≥1:8 and ≥1:128 and geometric mean titers (GMTs). Booster dose safety and tolerability were also evaluated. Results In both studies, the percentages of subjects with rSBA titers ≥1:8 through 10 years postvaccination were generally higher or similar among MenACWY-TT (69.3%–91.2% at Year 10; n=137–163) compared with MenACWY-PS (24.4%–88.9%; n=45–53) recipients for all 4 serogroups (Figure); similar results were observed for GMTs (146.0–446.9 vs 12.9–191.0 at Year 10). One month after a MenACWY-TT booster dose, 97.7%–100% of subjects across groups had titers ≥1:8 (Figure), and GMTs were markedly higher than prebooster values. No new safety signals were identified following the booster dose. Figure 1. Subjects in each of the 2 studies with rSBA titers ≥1:8 before and at 1 month, 5 years, and 10 years after primary vaccination with MenACWY-TT or MenACWY-PS at 11–17 years of age and 1 month after booster vaccination with MenACWY-TT at 10 years following primary vaccination. Conclusion Functional antibodies for all 4 serogroups persisted through 10 years after MenACWY-TT adolescent vaccination, suggesting that this vaccine may help prevent IMD throughout the lengthy risk period in this group. A MenACWY-TT booster dose may further extend protection regardless of the primary vaccine received. Funded by Pfizer. Disclosures Paula Peyrani, MD, Pfizer Inc (Employee, Shareholder) Chris Webber, MD, Pfizer Inc (Employee, Shareholder) Cindy Burman, PharmD, Pfizer Inc (Employee, Shareholder) Paul Balmer, PhD, Pfizer Inc (Employee, Shareholder) John L. Perez, MD, MA, Pfizer Inc (Employee, Shareholder)

scholarly journals EVALUATION OF VACCINATION PROGRAMMES AGAINST GUMBORO DISEASE WITH PERSISTANCE OF MATERNALLY DERIVED ANTIBODY IN BROILER CHICKENS

2012 ◽  
Vol 3 (1) ◽  
pp. 13-16 ◽  
Author(s):  
BK Paul ◽  
AKMF Huque ◽  
SML Kabir ◽  
J Alam ◽  
SC Badhy
Keyword(s):  
Vaccination Programme ◽  
Broiler Chickens ◽  
Booster Dose ◽  
Primary Vaccination ◽  
Vaccination Schedule ◽  
Before And After ◽  
Bursal Disease ◽  
Antibody Titres ◽  
The Mean ◽  
Gumboro Disease

The study was carried out to evaluate the vaccination programmes with Nobilis® Gumboro D78 (Intervet, Netherland) against Gumboro disease with persistance of maternally derived antibody in broiler chickens during two month period from August to September 2003 in Sherpur district of Bangladesh. A total of seven farms were selected, of which owners of five farms practiced their own vaccination programme i.e., primary vaccination at 5 (three farms), 7 and 8 days old with no booster against infections bursal disease (IBD) whereas imposed vaccination schedule (primary vaccination at 14 days old with a booster at 28 days old) was implemented in the remaining two farms. The vaccination programmes were evaluated by determining the antibody titres before and after vaccination and by morbidity and mortality of the vaccinated chickens against Gumboro disease. The present investigation demonstrated that mortality of chickens occurred in farms in which the birds were vaccinated between 5 to 7 days of age. The present result revealed that 7 days after primary vaccination the titer level decreased significantly (p < 0.05) in all the farms in which the farmers followed their own vaccination schedule. The present result also demonstrated that the mean titer before primary vaccination was 1276.8 ± 43.84 but seven days after vaccination it increased (1434.2 ± 29.97) insignificantly (p > 0.05) and this increasing rend continued up to 14 days after vaccination that is upto the age of 28 days (1549.6 ± 33.38) and seven days after booster dose that is at the age of day 35 the mean titer increased (2886.60 ± 80.67) significantly (p < 0.05) in the remaining two farms where the imposed vaccination programme was implemented. The present results obviously demonstrated that maternal antibody level decreasing about half within five days and decreased to negative level (364.00 ± 9.25) by the day 20. From the present study it may be concluded that broiler birds may primarily be vaccinated at the age of around day 14 with a booster at 28 days old.

Sign in / Sign up

Export Citation Format

Share Document